nivolumab,relatlimab
bms
['047 ,(-nct047),(-0.047%),(-2047)', 'relativity,047', 'nivo']
unfortunately still no significant os benefit with real+nivo vs nivo alone in the #relativity-047 trial #asco23 
Professor in Cancer Surgery at Sahlgrenska University Hospital. @sahlgrenska @SahlgrenskaAcad @goteborgUni #wcmtm #melanoma #breastcancer #surgery